125I Seed Implantation Plus Systemic Therapy for Oligoprogressive NSCLC or Colorectal Cancer

125I Seed Implantation Plus Systemic Therapy for Oligoprogressive NSCLC or Colorectal Cancer is a phase 2, randomised interventional study registered as NCT07333651 by Li Min, with a registry enrolment figure of 90 participants, started 2026-01 and due to reach its primary completion in 2027-01-01. Interventions recorded: Standard-of-Care Systemic Therapy; 125I Seed Implantation. Conditions listed: Oligometastatic Disease. Primary outcome: Progression-Free Survival (PFS). Colorectal eligibility wording from the registry: "* Histologically or cytologically confirmed metastatic non-small cell lung cancer (NSCLC) or colorectal cancer (CRC)". Sites: China. No results are recorded here; the registry entry is the source.